Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

MLA

Shaheer Khan, et al. “Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy.” Frontiers in Oncology, vol. 12, June 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....51ce4b781e534d0833c4b3828b10358b&authtype=sso&custid=ns315887.

APA

Shaheer Khan, Jose Lutzky, Alexander N. Shoushtari, Joanne Jeter, Brian Marr, Thomas E. Olencki, Colleen M. Cebulla, Mohamed Abdel-Rahman, J. William Harbour, Naomi Sender, Alexandra Nesson, Shahnaz Singh-Kandah, Susana Hernandez, Jeanelle King, Manpreet S. Katari, Lyssa Dimapanat, Stephanie Izard, Grazia Ambrosini, Oliver Surriga, … Richard D. Carvajal. (2022). Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy. Frontiers in Oncology, 12.

Chicago

Shaheer Khan, Jose Lutzky, Alexander N. Shoushtari, Joanne Jeter, Brian Marr, Thomas E. Olencki, Colleen M. Cebulla, et al. 2022. “Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy.” Frontiers in Oncology 12 (June). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....51ce4b781e534d0833c4b3828b10358b&authtype=sso&custid=ns315887.